Two of the Biggest European Biotechs launch Antibody Program together

07/04/2016 - 2 minutes

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. 

morphosys_galapagos_inflammatory_mor106_ylanthiaJust after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for a novel monoclonal antibody.

This break into clinical development is the result of a collaboration between MorphoSys and Galapagos – two European billion-euro Biotechs.

The phase I trial will evaluate the safety of MOR106 in at least 56 healthy volunteers, and will be conducted in Belgium. As a secondary objective, it will also characterize how the drug performs in the human body (pharmacokinetics) and possible immunogenicity (that could lead to side effects).

The topline results of the complete study are expected in the second half of 2017. As previously agreed in the partnership, Galapagos and MorphoSys will equally share the research and development costs,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member